As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this free New Scientist podcast, we meet Professor Andrea Manfrin whose team is responsible for driving this change at the Medicines and Healthcare products Regulatory Agency.More from this series:In Episode 1 we meet the chair of the UK review into commercial clinical trials, James O'ShaughnessyIn Episode 3 we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development programRead more here and watch a video summarising the series.Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program.More from this series:In Episode 1 we meet the chair of the UK review into commercial clinical trials, James O'ShaughnessyIn Episode 2 we hear from Professor Andrea Manfrin whose team is responsible for driving this change at the Medicines and Healthcare products Regulatory AgencyRead more here and watch a video summarising the series.Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
The UK has long been a world leader for clinical trials and life sciences research. But after losing ground post-COVID and post-Brexit, the country has begun to rethink the landscape for clinical trials. In this free New Scientist podcast, we meet the chair of the UK review into commercial clinical trials, James O'Shaughnessy, and ask how the independent review has influenced the reinvention of the clinical trials infrastructure for a new age of medicine.More from this series:In Episode 2 we hear from Professor Andrea Manfrin whose team is responsible for driving this change at the Medicines and Healthcare products Regulatory AgencyIn Episode 3 we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development programRead more here and watch a video summarising the series.Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
FREMONT, Calif. (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the.